Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy
Quoin Pharmaceuticals announced peer-reviewed publication in Dermatology and Therapy of a paper introducing QRX003 and a pediatric compassionate-use case in Netherton Syndrome. After 21 months of once-daily whole-body treatment, the patient's skin improved from severe (IGA 4) to fully clear (IGA 0), itch fell from WI-NRS 5 to 0, and no treatment-related adverse events were reported — the longest continuous QRX003 exposure to date.
Key figures
- Drug Name
- QRX003
- Phase Of Trial
- Phase 2/3
- Topline data timing
- Q2 2027
- Recruitment completion
- by end of 2026
- Compassionate use exposure
- 21 months in a pediatric patient, IGA improved from 4 to 0, WI-NRS from 5 to 0
- Phase 2 3 target enrollment
- 20
- Interim primary endpoint hit rate
- 4 of 6 participants (66.7%) achieved ≥1-grade IGA improvement, p=0.0087 vs pre-specified alpha 0.0215
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.